APA (7th ed.) Citation

Chounta, V., Overton, E. T., Mills, A., Swindells, S., Benn, P. D., Vanveggel, S., . . . Spreen, W. R. (2021). Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M). The patient : patient-centered outcomes research, 14(6), 849-862. https://doi.org/10.1007/s40271-021-00524-0

Chicago Style (17th ed.) Citation

Chounta, Vasiliki, et al. "Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)." The Patient : Patient-centered Outcomes Research 14, no. 6 (2021): 849-862. https://doi.org/10.1007/s40271-021-00524-0.

MLA (9th ed.) Citation

Chounta, Vasiliki, et al. "Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)." The Patient : Patient-centered Outcomes Research, vol. 14, no. 6, 2021, pp. 849-862, https://doi.org/10.1007/s40271-021-00524-0.